Purpose: With the advent of gene therapies for inherited retinal degenerations (IRDs), genetic diagnostics will have an increasing role in clinical decision-making. Yet the genetic cause of disease cannot be identified using exon-based sequencing for a significant portion of patients.
INTRODUCTION
Inherited retinal degenerations (IRDs) are a group of monogenic diseases that are the most common cause of blindness in the working age population 1 . About 260 genes have been associated with IRDs with functions spanning almost every aspect of cellular function: from splicing machinery, to microtubular transport and phototransduction 1 . State-of-the-art clinical diagnostics using next-generation sequencing (NGS) of known IRD genes successfully identifies the causal mutation in only 50 to 70% of cases 2, 3 . Although copy number changes 4 and intronic mutations 5 contribute to disease, they are not routinely assessed and likely contribute to the genetic causality in a significant portion of currently unsolved cases. With the advent of successful gene therapies for IRDs 6 , understanding such non-coding mutations and developing assays to evaluate them is of increasing importance. One example is the autosomal recessive RPGRIP1-associated disease which is an attractive candidate for gene therapy with already established success in murine 7 and canine 8 models. Yet, almost all of the mutations in RPGRIP1
have been described in the coding-region 9 .
RPGRIP1 plays a critical role in opsin trafficking, outer-segment disc organization and photoreceptor survival 10, 11 . While it primarily localizes to the transition zone of rods and cones, various of its isoforms can be found in the outer segment, along the microtubules as well as in Technologies) and verified by Sanger sequencing. Colonies with the correct sequence and restriction enzyme pattern were then sub-cloned into the pCS2+GW vector (kind gift from Dr Erica Davis) via Gateway LR clonase II (Thermo Fisher) and similar analyses as before was done to isolate vectors with the appropriate inserts for transfection experiments. The final vector included RPGRIP1 exons 11-16 including extensions into intron 10 and 16 on the 5' and 3' ends, which was cloned into pCS2+GW and used for splicing assays.
Quantitative polymerase chain reactions (qPCR)
Five nanograms (ng) of genomic DNA, 200 nM of each primer and 10 µl of Fast SYBR Green
Master Mix (Life Technologies, Grand Island, NY) were used for qPCR reactions which were performed on a Stratagene Mx3000P instrument (Agilent Technologies) using the standard thermocycling program (95 °C for 3 min, 40 cycles of 95 °C for 20 s, and 60 °C for 1 min, followed by a melting curve). The ddCT method was used for the analysis of results where ZNF80 was used as a reference gene and an in-house DNA sample with wild type RPGRIP1 (OGI200) used for normalization. Each sample was tested in triplicate and the average value was used. Standard deviation with error propagation was used to calculate up and down errors.
Cell culture and transfections
Human embryonic kidney (HEK293T) and retinoblastoma (WERI-Rb1) cells purchased from American Type Culture Collection (ATCC, Manassas, VA) and maintained in RPMI medium supplemented with 10% Fetal Bovine Serum-1640 (Thermo Fisher). 2ml of 5 x 10 5 cells/ml were plated into each well of a 6-well plate (Corning Inc., Corning, NY) 12hrs prior to transfections.
1-5
μ g of vector DNA per well was used for transfections using a commercial reagent (Lipofectamine 2000, Invitrogen, Carlsbad, CA) . Cells were harvested for RNA extraction 48 hours after transfection.
RNA isolation and cDNA synthesis
Cells were lysed with TRIzol (Thermo Fisher). After BCP or chloroform (Sigma-Aldrich, St.
Louis, MO) treatment, the aqueous phase was transferred to mRNeasy columns with DNase I digestion performed on-column (Qiagen). Quantification was performed via NanoDrop (Thermo Fisher) and 500ng of RNA was converted to cDNA using oligo(dT) primers and SuperScript II (Thermo Fisher).
Splicing assay and amplicon sequencing
The mutant, control and wild-type vectors described above were transfected in to HEK293T and WERI-Rb1 cells. Two days post-transfection, cDNA was generated as described and RT-PCR performed amplifying the flanking exons of the point mutation of interest. The PCR products were purified by DNA-clean and concentrator kits (Zymo Research). Amplicon sequencing was then performed at the Massachusetts General Hospital Center for Computational and Integrative Biology, where the PCR products were fragmented using sonication and sequenced with the standard NGS pipeline. Visualization and analysis of the data were performed as described under bioinformatics.
Epigenetic features surrounding the RPGRIP1 locus
ATAC-Seq and ChIP-Seq were performed according to previously published methods 23, 24 . Figure S1 ). In the latter seven families no other significant mutations in RPGRIP1 or other IRD genes were identified. Since they were all diagnosed with an early onset IRD, a characteristic presentation of RPGRIP1 disease 25 , further testing was performed to search for non-coding and structural variants in RPGRIP1 or other IRD genes through whole exome and whole genome sequencing. Among these seven families, three of the second-allele mutations were predicted to be copy number changes and three were intronic mutations (Table 1) . In one family, OGI-578, we did not validate second pathogenic variants in RPGRIP1 ( Figure S1 ).
WES and WGS studies showed that three families have structural variants as the second mutation in RPGRIP1. Analysis of WES data showed that patient OGI-1797-3128 had a predicted deletion of exon 19 (Table 1) , which was confirmed by qPCR ( Figure S2 ). Exon 19 has 139 nucleotides, and thus its deletion is predicted to lead to a frameshift resulting in a premature stop codon and likely subsequent nonsense mediated decay (NMD) 26 . In OGI-281-608, the gain of a copy of exon 2 was detected through structural analysis 20 in addition to coverage-based predictions of WGS data. The structural change led to misalignment of paired-end reads ( Figure 1c and 1d), which indicated a tandem duplication. This mutation was validated by qPCR ( Figure   1b ), and the predicted breakpoint confirmed through PCR and Sanger sequencing (Figure 1e and 1f). Sanger sequencing also identified 135bp of missing DNA upstream of the breakpoint, suggesting a possible complex rearrangement as the causal event 27 . Given that exon 2 is 133bp, its tandem duplication would lead to a LoF allele.
Patient OGI-237-523 similarly had a tandem copy number gain but in both exons 1 and 2 detected by WES (Figure 2b ). The 5' breakpoint was mapped 2Kb upstream of exon 1 (Figures   2c, S3 ). However, given that the second copy would maintain 2Kb upstream of the exon 1, which would include a proximal presumed promoter (Figure 2c ), we questioned whether a second transcriptional start site (TSS) within the duplicated 5' upstream region would exclude the mutant exons 1' and 2' thus leading to normal transcription. Therefore, we hypothesized that perhaps a critical RPGRIP1 regulatory domain exists outside of 2Kb region upstream of exon 1.
Review of transcriptome data of normal human retina 28 revealed an additional exon upstream of the annotated transcript, which was identified by numerous split reads as well as high sequence coverage approximately 8Kb upstream of the annotated RPGRIP1 exon 1 (Figure 2d ). We further assessed this using ATAC-seq and ChIP-seq data, which showed open chromatin and transcription factor binding to this region and not to the previously annotated RPGRIP1 TSS ( Figure 2E ). These results suggest that the retinal TSS of RPGRIP1 and its regulatory regions are 8Kb upstream of the currently annotated exon 1. This also explains the likely pathogenic effect of the structural mutation seen in OGI-237-523. The tandem exon 1 and 2 duplication excludes a TSS and will lead to a premature stop-codon 29 codons past the start of the duplicated 5'UTR of exon 1. In OGI-601-1236, the c.1611+27G>A mutation led to a splicing pattern that became apparent only through amplicon sequencing (Figures 3b, S4, S5 ). In the WT allele, three splicing signals of various strengths were detected between exons 12 and 13 ( Figure 3b ). The two prominent splice variants have been annotated for RPGRIP1, the main event (9598 reads) being present in the NM_020366 transcript and indicating the canonical splice junction between exon 12 and 13. The second splice donor occurring 104bp into intron 12 (8499 reads) is part of the 5'UTR of predicted transcript model XM_005267881.3 (Figure 3b ). The third splice donor site occurs 227bp into intron 12 and has not been reported. In both the positive control, c.1611+1G>A, and the mutation under study, c.1611+27G>A, the primary splicing event that would lead to full-length protein failed to occur whereas the alternate transcript donor site, 104 past the NM_020366 exon 12, was preferred ( Figure 3b ). This variant would lead to a pre-mature 1 0
In OGI-949-1907, the intronic c.1468-263G>C variant identified resulted in an activation of a cryptic splice acceptor site 13bp past the mutation (Figure 3c ). The resultant cryptic exon 11', although 117bp and in-frame, has a premature stop codon four codons past the cryptic acceptor site. Thus the aberrant transcript will lead to NMD.
In order to account for potential differences in splicing between the neuronal and nonneuronal cell types 29 , all the splicing experiments were repeated with a retinoblastoma cell line WERI-Rb1, derived from photoreceptor cells 30 . The splicing changes resulting from the mutations assessed, led to similar patterns in both HEK293T as well as WERI-Rb1 lines ( Figure   S5 ). Overall, we found four novel non-coding mutations, four unreported coding mutations in RPGRIP1 ( Figure 4 ) and we have corrected the transcript model for RPGRIP1 in the retina with a new TSS and 5' exon 8kb upstream of the annotated exon 1 (name exon 1n in this paper).
Among the seven families with one LoF RPGRIP1 allele, OGI-578 did not reveal a second RPGRIP1 mutation after WGS and copy number analyses. None of the RPGRIP1 calls showed proper segregation or were of poor quality and failed Sanger validation. WGS however, revelaed other IRD candidate gene, the most prominent of which was CNGA1 with biallelic high quality calls.
DISCUSSION
In our analysis of nine families with biallelic RPGRIP1 mutations, six had a second non-coding mutation leading to a LoF allele. This not only highlights the importance of non-coding mutations in pathogenesis of recessive IRDs, but also implies a greater prevalence of RPGRIP1 mediated disease than previously thought. Three among the 1722 IRD families had bilallelic coding mutations in RPGRIP1, which corresponds roughly to the previously reported rates in the literature (0.17% vs 0.25%1 1 rate increased from 0.17% to 0.51%. This significant increase in frequency of RPGRIP1 mediated disease is still likely an underestimate given the bias of choosing samples with one LoF coding sequence mutation. Considering the possibility of bialleleic non-coding LoF alleles, the rate of RPGRIP1 mediated disease is likely to be much greater than what was previously thought.
In the six families solved with the addition of structural and intronic mutation analyses, we validated the second LoF mutations in vitro showing aberrations in the reading-frame caused by splicing or copy number changes. While deletions are simpler to interpret given clear interruption of reading frame, copy number gains can be just as disruptive. In both cases of copy number gain, OGI-237 and OGI-281, the mutations were tandem duplications leading to premature stop codons. While investigating the potentially pathogenic effect of the duplication in the first two annotated RPGRIP1 exons in OGI-237, we discovered a novel exon and a retinal TSS 8Kb upstream of the previously annotated transcriptional start site. This is important as mutations in regulatory regions and 5'UTR have been shown to be disease-causing, such as in the case of PRPF31 and OPN1MW 9 . We propose the inclusion of this RPGRIP1 exon, chr14:21748265-21748318 (hg19), in future IRD diagnostic panels.
We also detected three mutations causing intron retentions or inclusion of cryptic exons in the resulting transcripts, two of which were in the flanking 30bp of annotated exons. Weakening of splicing between exons 15 and 16 with this mutation is supportive of both models.
Splicing is a tissue-specific phenomenon and neuronal tissues have a unique splicing machinery that can lead to unique exonic retentions 29 . Thus the splicing patterns we identified in HEK293T cells were confirmed in a retina relevant line. We chose WERI-Rb1, a retinoblastoma line shown to possess the neuronal specific splicing machinery 29 . Although we did not detect a significant difference between the two lines ( Figure S5 ), we foresee a benefit in using a tissue relevant cell line, such as WERI-Rb1 for IRDs, when assessing splicing mutations.
Despite the decreasing costs of whole genome sequencing, it is still not feasible for routine clinical assessment. Hence, assessing for non-coding mutations in RPGRIP1 and other recessive IRD genes still demands a step-wise approach to reduce screening costs. 4 . T h e L a n c e t . 7 . 3 5 . These PCR products were used for the subsequent amplicon-seq analyses. 
